文献速递中医内科针灸推拿中医康复

中医非药物疗法辅助改善重症COVID-19呼吸症状的多中心随机对照试验

Effectiveness and safety of adjunctive non-drug measures in improving respiratory symptoms among patients with severe COVID-19: A multicenter randomized controlled trial.
PubMed 文献 · J Integr Med · 2024-09-17

本研究为多中心、评估者盲法随机对照试验,纳入198例重症COVID-19住院患者,比较中医非药物措施联合俯卧位通气与单纯俯卧位通气5天的疗效。结果显示联合治疗组SpO2改善比例显著更高(91% vs 75.3%,MD=15.7,95%CI 4.4-27.1,P=0.008),呼吸症状评分更低(MD=-1.7,95%CI -2.8至-0.5,P=0.008),但呼吸频率组间无差异,改善率无差异。

要点

  • 中医非药物措施联合俯卧位通气可显著提高重症COVID-19患者SpO2改善比例。
  • 联合治疗在干预第3天后呼吸症状评分显著低于单纯俯卧位通气。
  • 两组呼吸频率变化及改善率无显著差异,安全性需关注不良事件。

核心结论

  • 中医非药物措施联合俯卧位通气可有效治疗重症COVID-19,显著提高SpO2并改善症状评分,但改善率组间无差异。

研究设计与样本

  • 多中心、评估者盲法随机对照试验,纳入198例重症COVID-19住院患者,治疗组接受个体化中医非药物措施联合俯卧位通气,对照组仅俯卧位通气,连续5天。

主要发现

  • 干预结束时治疗组91%(71例)患者SpO2高于93%,对照组75.3%(61例)达到该水平。
  • SpO2改善比例治疗组显著更高(MD=15.7,95%CI 4.4-27.1,P=0.008)。
  • 治疗第3天后治疗组呼吸相关症状评分低于对照组(MD=-1.7,95%CI -2.8至-0.5,P=0.008)。
  • 两组呼吸频率每日均较基线显著下降,但组间无统计学差异(均P≥0.05)。
  • 干预期间发生31例不良事件,2例因病情恶化转入ICU。

关键数值与推荐

  • 主要结局为5天干预结束时SpO2改善患者百分比及呼吸频率变化。
  • SpO2改善率定义为连续3天SpO2升高。
  • 治疗组SpO2改善比例91%,对照组75.3%,MD=15.7(95%CI 4.4-27.1,P=0.008)。
  • 呼吸症状评分MD=-1.7(95%CI -2.8至-0.5,P=0.008)。

临床怎么用

  • 对重症COVID-19住院患者,可在俯卧位通气基础上加用个体化中医非药物措施以改善氧饱和度和呼吸症状。
  • 需监测不良事件,病情恶化时及时转ICU。

局限性

  • 39例(19.7%)患者退出研究,可能影响结果解释。
  • 改善率组间无差异,提示部分结局指标获益有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The outbreak of coronavirus disease 2019 (COVID-19) infection posed a huge threat and burden to public healthcare in late 2022. Non-drug measures of traditional Chinese medicine (TCM), such as acupuncture, cupping and moxibustion, are commonly used as adjuncts in China to help in severe cases, but their effects remain unclear. OBJECTIVES: To observe the clinical effect of TCM non-drug measures in improving respiratory function and symptoms among patients with severe COVID-19. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This study was designed as a multicenter, assessor-blind, randomized controlled trial. Hospitalized patients with COVID-19 were randomly assigned to the treatment or control group. The treatment group received individualized TCM non-drug measures in combination with prone position ventilation, while the control group received prone position ventilation only for 5 consecutive days. MAIN OUTCOME MEASURES: The primary outcome measures were the percentage of patients with improved oxygen saturation (SpO2) at the end of the 5-day intervention, as well as changes of patients' respiratory rates. The secondary outcome measures included changes in SpO2 and total score on the self-made respiratory symptom scale. The improvement rate, defined as a 3-day consecutive increase in SpO2, the duration of prone positioning, and adverse events were recorded as well. RESULTS: Among the 198 patients included in the intention-to-treat analysis, 159 (80.3%) completed all assessments on day 5, and 39 (19.7%) patients withdrew from the study. At the end of the intervention, 71 (91%) patients in the treatment group had SpO2 above 93%, while 61 (75.3%) in the control group reached this level. The proportion of participant with improved SpO2 was significantly greater in the intervention group (mean difference [MD] = 15.7; 95% confidence interval [CI]: 4.4, 27.1; P = 0.008). Compared to the baseline, with daily treatment there were significant daily decreases in respiratory rates in both groups, but no statistical differences between groups were found (all P ≥ 0.05). Compared to the control group, the respiratory-related symptoms score was lower among patients in the treatment group (MD = -1.7; 95% CI: -2.8, -0.5; P = 0.008) after day 3 of treatment. A gradual decrease in the total scores of both groups was also observed. Thirty-one adverse events occurred during the intervention, and 2 patients were transferred to the intensive care unit due to deterioration of their illness. CONCLUSION: TCM non-drug measures combined with prone positioning can effectively treat patients with severe COVID-19. The combined therapy significantly increased SpO2 and improved symptom scores compared to prone positioning alone, thus improving the patients' respiratory function to help them recover. However, the improvement rate did not differ between the two groups. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2300068319). Please cite this article as: Yin X, Jin Z, Li F, Huang L, Hu YM, Zhu BC, Wang ZQ, Li XY, Li JP, Lao LX, Mi YQ, Xu SF. Effectiveness and safety of adjunctive non-drug measures in improving respiratory symptoms among patients with severe COVID-19: A multicenter randomized controlled trial. J Integr Med. 2024; 22(6): 637-644.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Yin X, Jin Z, Li F, et al. Effectiveness and safety of adjunctive non-drug measures in improving respiratory symptoms among patients with severe COVID-19: A multicenter randomized controlled trial. J Integr Med. 2024. PMID: 39358063. doi:10.1016/j.joim.2024.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。